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Approximately 15% of patients with colorectal cancer are found
to have stage IV disease at diagnosis and up to 50% will develop
metastatic disease in the liver at some point during the course of
disease.1 Furthermore, only 10–20% of all patients with stage IV
disease are eligible for potentially curable resection. Median sur-
vival in patients with untreated colorectal liver metastases (CLM)
is 8 months.2 Previously, the only active chemotherapeutic agent
for metastatic colorectal cancer was 5-fluorouracil (5-FU), which
produced response rates of 10–20% and extended median survival
to 1 year. The addition of novel cytotoxic drugs, such as oxalipl-
atin, irinotecan and capecitabine, and targeted therapies, such as
bevacizumab, cetuximab and panitumumab, to standard regi-
mens has dramatically extended overall survival to >20 months.3
Despite this progress, 5-year survivors treated with chemotherapy
alone are few. However, in parallel with the pace of drug develop-
ment, increases in the utilization and safety of hepatic resection, as
well as improvements in preoperative imaging and selection
during this period, have doubled 5-year survival rates from 30%
to 60%.4,5 Studies have confirmed that the use of combined-
modality therapy has resulted in measurable 10-year survivors.6
However, several issues remain to be resolved, including that of
how to properly identify candidates for curative resection. The
liver surgeon is frequently presented with four categories of CLM
patient: those who are easily resectable; those who are borderline
resectable; those who are unresectable but may be converted to
resectable, and patients who are unlikely ever to be resectable.
Proceeding straight to surgery has been the paradigm for the first
group and chemotherapy or other non-resection liver-directed
therapies have been reserved for the fourth group. The second and
third groups have more recently been managed with a trial of
neoadjuvant chemotherapy intended to downstage the tumour,
allow for parenchymal-sparing hepatectomy and increase the
probability of a margin-negative resection. Evidence from the
European Organization for Research and Treatment of Cancer
(EORTC) Intergroup 40983 trial demonstrated that in patients
who underwent resection of up to four metastatic liver lesions,
perioperative chemotherapy with FOLFOX [folinic acid (leucov-
orin), 5-FU, oxaliplatin] increased 3-year progression-free sur-
vival by 9.2% compared with surgery alone.7 Recent refinements
in surgical technique incorporating ablative techniques, portal
vein embolization, staged resections and hepatic arterial pump
therapy have allowed the definition of resectable CLM to evolve
beyond the parameters of size, location and number of tumours.
Presently, in order for CLM to be considered resectable, it must
be removable with a negative margin and allow for the preserva-
tion of at least two contiguous, functional liver segments with
intact portal and arterial inflow, venous outflow and biliary drain-
age. Additionally, as the future liver remnant (FLR) depends criti-
cally on functional liver parenchyma, it can be as small as 20% of
total liver volume (TLV) in a patient with a normal liver, but an
FLR injured by chemotherapy may need to represent 30% of TLV
and one with fibrosis from cirrhosis may be required to represent
as much as 40% of TLV.8 Lastly, the biologic behaviour of the
tumour must be taken into account such that only those patients
whose tumours contain limited, controllable extrahepatic disease9
and demonstrate a response to preoperative chemotherapy10
should be considered for resection from an oncologic standpoint.
The current study by Mohammed et al.11 addresses contempo-
rary hepatic surgeon perceptions of resectability of CLM. The
authors presented 10 scenarios ranging from a solitary, peripheral
lesion to extensive bilobar involvement to a cohort of hepatobil-
iary and transplant surgeons in Canadian academic centres.11 The
surgeons were asked to evaluate cross-sectional computed tomog-
raphy images and to determine whether they would be amenable
to surgical removal in each case with or without adjunctive thera-
pies such as radiofrequency ablation, portal vein embolization and
staged resection. To control for medical and oncologic factors, the
surgeons were told that patients had already received six courses of
neoadjuvant chemotherapy (with no progression of disease) and
were fit for an operation. Although there was absolute agreement
in the two scenarios of clearly resectable and unresectable disease,
there was a marked divergence in opinion on the remainder of
DOI:10.1111/j.1477-2574.2012.00451.x HPB
HPB 2012, 14, 283–284 © 2012 International Hepato-Pancreato-Biliary Association
the cases and only one additional case achieved a consensus. The
observation of differing opinion in over half of the scenarios
and little agreement on the type and number of non-resectional
adjuncts to surgery11 highlights the need for a standardized
approach to these patients based on the highest levels of evidence-
based practice. Given the lack of randomized trials, varying defi-
nitions of resectability in different studies and rapid introduction
of novel technologies, we must rely on established guidelines to
direct therapeutic decisions. In fact, in the study by Mohammed
et al.,11 when the surgeons were asked to give reasons for their
decisions, the majority referenced the 2006 American Hepato-
Pancreato-Biliary Association (AHPBA)/Society of Surgical
Oncology (SSO)/Society for Surgery of the Alimentary Tract
(SSAT) Consensus Conference on the Multidiscliplinary Treat-
ment of Colorectal Liver Metastasis. Updated recommendations
were presented last month in San Francisco at the 2012 American
Society of Clinical Oncology Gastrointestinal Cancers Sympo-
sium, sponsored by the same societies, and a new consensus state-
ment should be published within the year.
It is therefore not surprising that there exists significant hetero-
geneity in approaches to the patient with CLM in the hepatopan-
creatobiliary academic community and the present study11 only
affirms that we still have much to learn. For example, other issues,
such as the proper timing of chemotherapy, treatment of synchro-
nous disease and management of disappearing lesions, still need
further investigation. Meanwhile, as Mohammed et al.11 point out,
it is imperative that CLM patients be evaluated in a multidisci-
plinary tumour board setting by all surgical and oncologic spe-
cialists who treat this disease in order to identify those who may
potentially benefit from hepatic resection. The definition of this
population is clearly still evolving.
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